Literature DB >> 2546846

Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat.

M E Cooper1, T J Allen, P A Macmillan, B E Clarke, G Jerums, A E Doyle.   

Abstract

This study has evaluated the effects of the angiotensin converting enzyme inhibitor Enalapril on glomerular ultrastructure and albuminuria in normotensive and hypertensive diabetic rats. Streptozotocin-diabetes was induced in Wistar Kyoto and spontaneously hypertensive rats. Enalapril was administered in drinking water in diabetic normotensive, control hypertensive and diabetic hypertensive rats. Enalapril therapy prevented an increase in glomerular basement membrane thickness in diabetic normotensive, control hypertensive and diabetic hypertensive rats without any significant effect on fractional mesangial volume. Enalapril decreased albuminuria in diabetic normotensive, control hypertensive and diabetic hypertensive rats. Thus, enalapril retards the development of glomerular basement membrane thickening and albuminuria in the rat, in the presence or absence of hypertension.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2546846     DOI： 10.1007/BF00265552

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


  8 in total

1.  Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy.

Authors:  E Hommel; H H Parving; E Mathiesen; B Edsberg; M Damkjaer Nielsen; J Giese
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-23

Review 2.  Current status of capillary basement-membrane disease in diabetes mellitus.

Authors:  J R Williamson; C Kilo
Journal:  Diabetes       Date:  1977-01       Impact factor: 9.461

3.  Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria.

Authors:  M Marre; H Leblanc; L Suarez; T T Guyenne; J Ménard; P Passa
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-06

4.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.

Authors:  R Zatz; B R Dunn; T W Meyer; S Anderson; H G Rennke; B M Brenner
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

5.  Glomerular hemodynamics in experimental diabetes mellitus.

Authors:  T H Hostetter; J L Troy; B M Brenner
Journal:  Kidney Int       Date:  1981-03       Impact factor: 10.612

6.  Evidence against increased glomerular pressure initiating diabetic nephropathy.

Authors:  N Bank; R Klose; H S Aynedjian; D Nguyen; L B Sablay
Journal:  Kidney Int       Date:  1987-04       Impact factor: 10.612

7.  Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat.

Authors:  M E Cooper; T J Allen; P Macmillan; L Bach; G Jerums; A E Doyle
Journal:  Am J Hypertens       Date:  1988-01       Impact factor: 2.689

8.  Effects of genetic hypertension on diabetic nephropathy in the rat--functional and structural characteristics.

Authors:  M E Cooper; T J Allen; R C O'Brien; P A Macmillan; B Clarke; G Jerums; A E Doyle
Journal:  J Hypertens       Date:  1988-12       Impact factor: 4.844
  8 in total
  19 in total

Review 1.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

2.  The effect of intrauterine environment and low glomerular number on the histological changes in diabetic glomerulosclerosis.

Authors:  S E Jones; K E White; A Flyvbjerg; S M Marshall
Journal:  Diabetologia       Date:  2005-12-09       Impact factor: 10.122

3.  Diabetes: RAS inhibition: probably not a one-size-fits-all approach.

Authors:  Drazenka Pongrac Barlovic; Mark E Cooper
Journal:  Nat Rev Nephrol       Date:  2009-12       Impact factor: 28.314

Review 4.  Recent Advances in Pharmacological Management of Hypertension in Diabetic Patients with Nephropathy : Effects of Antihypertensive Drugs on Kidney Function and Insulin Sensitivity.

Authors:  Tsuneharu Baba; Takashi Ishizaki
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

Review 5.  Diabetic vascular injury and ACE. Potential for pharmacological prevention of complications of later life.

Authors:  M E Cooper; D Vranes; J R Rumble
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

6.  Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat: are these effects specific for enalapril?

Authors:  T Baba; P T Sawicki
Journal:  Diabetologia       Date:  1989-11       Impact factor: 10.122

7.  Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy.

Authors:  B J Davis; C I Johnston; L M Burrell; W C Burns; E Kubota; Z Cao; M E Cooper; T J Allen
Journal:  Diabetologia       Date:  2003-06-28       Impact factor: 10.122

Review 8.  The natural progression of kidney injury in young type 1 diabetic patients.

Authors:  Julia M Steinke
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

9.  The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.

Authors:  A M D Watson; J Li; C Schumacher; M de Gasparo; B Feng; M C Thomas; T J Allen; M E Cooper; K A M Jandeleit-Dahm
Journal:  Diabetologia       Date:  2009-10-28       Impact factor: 10.122

Review 10.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.